Attached files
file | filename |
---|---|
8-K - FORM 8-K - VALEANT PHARMACEUTICALS INTERNATIONAL | a55724e8vk.htm |
Exhibit 99.1
International Headquarters
One Enterprise Aliso Viejo, CA 92656
949.461.6000 FAX 949.461.6636
One Enterprise Aliso Viejo, CA 92656
949.461.6000 FAX 949.461.6636
Contact:
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002
laurie.little@valeant.com
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002
laurie.little@valeant.com
VALEANT PHARMACEUTICALS ANNOUNCES PRICING OF SENIOR NOTES
ALISO
VIEJO, Calif., April 7, 2010 Valeant Pharmaceuticals International (NYSE: VRX) announced
today that it has priced its previously announced private placement
of $400 million of 7.625%
senior unsecured notes due 2020. The principal amount was increased from the previously announced
$350 million. The senior unsecured notes were priced at par and will be
issued by the Company and jointly and severally guaranteed by certain of the Companys
subsidiaries, which initially shall be the same subsidiaries that guarantee the Companys
outstanding 8.375% Senior Notes Due 2016. The Company intends to use the net proceeds from this
offering to repurchase 3.0% Convertible Subordinated Notes due 2010 of the Company and other
securities of the Company, to finance the acquisition of a private branded generics and
over-the-counter company located in Brazil for which the Company has signed a binding agreement and
for other general corporate purposes.
The notes will not initially be registered under the Securities Act of 1933, as amended (the
Securities Act), or any state securities law and may not be offered or sold in the United States
absent registration or an applicable exemption from registration under the Securities Act and
applicable state securities laws. The notes will be offered only to qualified institutional buyers
under Rule 144A and outside the United States in compliance with Regulation S under the Securities
Act. This press release does not constitute an offer to sell any security and shall not constitute
an offer, solicitation or sale in any jurisdiction in which such offer or sale would be unlawful.
About Valeant
Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of products primarily in the areas of
neurology and dermatology. More information about Valeant can be found at www.valeant.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including, but not limited to, statements
regarding the offering by the Company of 7.625% senior unsecured notes due 2020 and the
anticipated use of the net proceeds from the issuance thereof. These statements are based upon the
current expectations and beliefs of management and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not limited to, risks and uncertainties
related to market and other conditions, including, among other things, related to the offering of
the Companys 7.625% senior unsecured notes due 2020, and the other risks and uncertainties
discussed in the Companys most recent annual or quarterly report filed with the SEC, which factors
are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of
the forward-looking statements, which speak only as of the date of this release. The Company
undertakes no obligation to update any of these forward-looking statements to reflect events or
circumstances after the date of this release or to reflect actual outcomes.
# # #